Making the case for oral chemotherapy in advanced NSCLC

Not all patients with advanced non-small-cell lung cancer (NSCLC) are eligible for platinum-based chemotherapy. Oral vinorelbine may be a valuable treatment option for frail and older patients in both first- and subsequent-line settings due to its manageable safety profile.

Professor Christos Chouaid of Department of Pneumology and Thoracic Oncology, Intercommunal Hospital of Creteil, France compared the efficacy and benefits of oral and intravenous (IV) vinorelbine and shared insights into combining vinorelbine with other treatment modalities, including immunotherapy and radiotherapy.